Misonix has completed its previously announced acquisition of privately held Solsys Medical in an all-stock transaction valued at approximately $109 million on the date prior to closing. A press release reports that Solsys and its leading cellular and tissue-based wound treatment, TheraSkin, is highly complementary to Misonix’s cutting-edge ultrasonic wound debridement solution, SonicOne—providing Misonix with a large direct advanced wound [...]